证券代码：301333 证券简称：诺思格 公告编号：2025-035 诺思格（北京）医药科技股份有限公司 第五届董事会第十二次会议决议公告 表决情况：9票同意；0票弃权；0票反对。 经审议，董事会认为：公司2025年半年度报告全文及其摘要内容真实、准确、 完整地反映了公司2025年半年度经营的实际情况，不存在任何虚假记载、误导性 陈述或者重大遗漏；报告编制和审核的程序符合法律、行政法规的要求，符合中 国证监会和深圳证券交易所的相关规定，同意对外报出。 公司董事会审计委员会已审议通过该议案。 具体内容详见公司同日于巨潮资讯网（http://www.cninfo.com.cn）披露的 《2025年半年度报告》和《2025年半年度报告摘要》（公告编号：2025-037）。 （二）审议通过《关于<2025年半年度募集资金存放与使用情况的专项报告> 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 诺思格（北京）医药科技股份有限公司（以下简称"公司"）第五届董事会 第十二次会议（以下简称"本次会议"）于2025年8月27日在公司会议室以现场结 合通 ...

诺思格（北京）医药科技股份有限公司 2025 年半年度报告全文 诺思格（北京）医药科技股份有限公司 2025 年半年度报告 2025 年 8 月 1 诺思格（北京）医药科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人 WU JIE（武杰）、主管会计工作负责人赵倩及会计机构负责 人(会计主管人员)赵李林声明：保证本半年度报告中财务报告的真实、准确、 完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中涉及未来的经营计划、业绩预测等方面的陈述，并不构成公司 对任何投资者及相关人士的实质性承诺，投资者及相关人士均应对此保持足 够的风险认识，并且应当理解计划、预测与承诺之间的差异。 公司在经营中可能面临的风险因素详见本报告"第三节 管理层讨论与分 析"之"十、公司面临的风险和应对措施"相关内容，敬请广大投资者予以 关注，并注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 三、其他相关资料。 ...

诺思格公告，2025年上半年营业收入3.8亿元，同比增长0.18%。净利润6111.61万元，同比增长4.45%。 ...

证券日报网讯诺思格（301333）8月27日在互动平台回答投资者提问时表示，公司将竭尽全力为客户提 供优质服务，努力提升经营业绩回报股东信任。 ...

Core Viewpoint - The company, Nossger (301333), aims to enhance management efficiency and strengthen competitive advantages to provide high-quality services to customers [1] Group 1 - The company will base its strategies on its own development plans [1] - The focus will be on improving management efficiency [1] - The company is committed to maximizing efforts in delivering quality services to clients [1]

Group 1 - The core viewpoint is that AI technology is gradually impacting various industries, and the company is closely monitoring these developments [1] - The company is independently developing an AI platform for relevant service areas to enhance internal work efficiency [1]

Company Overview - Norscog (Beijing) Pharmaceutical Technology Co., Ltd. specializes in providing integrated drug clinical research and development services for global pharmaceutical companies and research institutions [1] - The main products include clinical trial operation services, clinical trial site management services, data management and statistical analysis services, biological sample testing services, clinical trial consulting services, and clinical pharmacology services [1] Financial Performance - For Q1 2025, the company reported revenue of 173 million yuan, a year-on-year decrease of 2.53% [1] - The net profit for the same period was 26.07 million yuan, reflecting a year-on-year increase of 13.12% [1] - The sales gross margin stood at 36.53% [1] Market Position - As of August 20, Norscog's stock closed at 54.8 yuan, down 2.73%, with a rolling price-to-earnings (PE) ratio of 36.95 times [1] - The total market capitalization is 5.293 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical services sector is 49.21 times, with a median of 65.65 times, placing Norscog at 23rd in the industry ranking [1][2] Institutional Holdings - As of Q1 2025, only one institution holds shares in Norscog, which is a fund with a total holding of 12,400 shares valued at 0.01 million yuan [1]

金融界消息 截至2025年8月13日收盘，诺思格（301333）报收于56.35元，上涨2.72%，换手率5.73%， 成交量3.28万手，成交金额1.83亿元。 资金流向方面，今日主力资金净流入1156.06万元，占比成交额6.3%。其中，超大单净流出554.56万 元、占成交额3.02%，大单净流入1710.62万元、占成交额9.33%，中单净流出流出865.79万元、占成交 额4.72%，小单净流出290.27万元、占成交额1.58%。 天眼查商业履历信息显示，诺思格(北京)医药科技股份有限公司，成立于2008年，位于北京市，是一家 以从事研究和试验发展为主的企业。企业注册资本9658.1256万人民币，实缴资本9658.1256万人民币。 公司法定代表人为武杰。 通过天眼查大数据分析，诺思格(北京)医药科技股份有限公司共对外投资了7家企业，参与招投标项目 10次，知识产权方面有商标信息7条，专利信息3条，此外企业还拥有行政许可3个。 来源：金融界 诺思格最新一期业绩显示，截至2025一季报，公司营业总收入1.73亿元、同比减少2.53%，归属净利润 2607.37万元，同比增长13.12%，扣非净利润 ...

Summary of Key Points Core Viewpoint - The 2024 A-share Secretary Data Report indicates that the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan, highlighting the significant role of secretaries in connecting investors and listed companies [1][2]. Group 1: Overall Salary and Demographics - The total salary for A-share listed company secretaries in 2024 is 4.086 billion yuan, with an average annual salary of 754,300 yuan [1]. - Among the secretaries, those aged 40 and below constitute 43% of the market, while those aged 50 and above account for 22% [1]. - The educational background of secretaries shows that 34% hold a bachelor's degree, 52% have a master's degree, and 14% possess a doctoral degree [1]. Group 2: Industry-Specific Salary Insights - The average annual salary for secretaries in the pharmaceutical and medical service sector is 839,200 yuan [2]. - The distribution of salaries shows that 24% earn below 500,000 yuan, 48% earn between 500,000 and 1 million yuan, and 28% earn above 1 million yuan [2]. - The top three highest-paid secretaries are Gilbert Shing Chung Li from Kanglong Chemical with 1.9855 million yuan, Gao Dapeng from Zhaoyan New Drug with 1.7384 million yuan, and Xu Xiangke from Kailaiying with 1.6114 million yuan [2].

Core Insights - The report highlights that in 2024, the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the medical and healthcare services sector is 839,200 yuan [2] - The distribution of salaries shows that 24% earn below 500,000 yuan, 48% earn between 500,000 and 1 million yuan, and 28% earn above 1 million yuan [2] - The top three highest-paid company secretaries are Gilbert Shing Chung Li from Kanglong Chemical with 1.9855 million yuan, Gao Dapeng from Zhaoyan New Drug with 1.7384 million yuan, and Xu Xiangke from Kailaiying with 1.6114 million yuan [2] Age and Education Distribution - Company secretaries aged 40 and below constitute 43% of the market, while those aged 50 and above account for 22% [1] - The educational background of company secretaries shows that 34% hold a bachelor's degree, 52% have a master's degree, and 14% possess a doctoral degree [1] - Among the doctoral degree holders, there are 7 individuals, with the only full-time doctoral company secretary in the industry being Cao Nai'en from Huaxia Eye Hospital [1]